- Home
- AMC vs AMLX Comparison
AMC vs AMLX Comparison
Compare AMC & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMC | AMLX |
|---|---|---|
| Founded | 1920 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMC | AMLX |
|---|---|---|
| Price | $2.60 | $34.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $2.03 | ★ $21.56 |
| AVG Volume (30 Days) | ★ 18.1M | 3.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | $380,786,000.00 |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.57 | ★ 1612.94 |
| 52 Week Low | $0.93 | $9.71 |
| 52 Week High | $3.18 | $41.14 |
Technical Indicators
Market Signals| Indicator | AMC | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 65.07 |
| Support Level | $2.32 | $12.86 |
| Resistance Level | $3.00 | $41.14 |
| Average True Range (ATR) | 0.14 | 2.44 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 61.41 | 68.18 |
Price Performance
Historical ComparisonAbout AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.